Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 38 |
| Active Pipeline (Recruiting Now) | 6 (0) |
| Completed vs Stopped Early | 18 / 4 (10.5%) |
| Median Closed Actual Enrollment | 214 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Samsung Medical Center | Seoul, Gangnam-Gu | 3 |
| Asan Medical Center | Seoul | 3 |
| Seoul National University Hospital | Seoul | 2 |
Explore interactive annual charts and M&A subsidiary rollups in the Daewoong Pharmaceutical Co Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.